These constraints in the BTNX NTS are remarkably appropriate, as we identified e.g. etodesnitazene to obtain an identical in vitro potency and efficacy as fentanyl [7, 13] and as it may likely give PWUD a Untrue perception of basic safety. Also, the detectability of nitazene analogues in drug samples could be impacted by solubility concerns, as hig